Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial (CIRCA-19 RCT)

Ottawa Hospital Research Institute

Status and phase: Completed; Phase 2

Conditions: Acute Respiratory Distress Syndrome; Covid19

Treatments: Biological: UC-MSCs; Biological: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04865107

CIRCA-19 RCT

Details and patient eligibility

About

This is a Phase 2 multicenter randomized (2:1), placebo-controlled trial to evaluate early signs of efficacy of allogeneic, umbilical cord-derived (UC) mesenchymal stromal cells (MSCs) in patients with COVID-19 and Acute Respiratory Distress Syndrome (ARDS).

Randomized participants (N=54) will receive 3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs) or blinded placebo. The MSC product will be provided as 2.5 million cells/ml suspended in PlasmaLyte A containing 5% Human Albumin. The appearance-matched placebo product contains the same excipients, PlasmaLyte A and 5% Human Albumin, as the UC-MSCs.

Enrollment: 22 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age of ≥18 years
• Laboratory-confirmed SARS-CoV-2 infection during the current admission
• On invasive, non-invasive mechanical ventilation (NIV) (PEEP ≥5 cmH20) or high-flow nasal canula (HFNC) oxygen therapy (minimum total flow rate of 40 lpm)
• ARDS (onset <96h) as per the international consensus definition (P/F ratio < 300 with PEEP ≥5cm H20 or on HFNC), not due primarily to cardiac causes.

Exclusion criteria

• No consent/inability to obtain consent
• Rockwood Clinical Frailty Score > 4
• Moribund patient not expected to survive 24 hours
• Any other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%
• Currently receiving extracorporeal life support
• Pregnant or lactating
• Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
• Moderate to severe chronic liver disease (Childs-Pugh Score > 12)
• Severe chronic respiratory disease with a baseline PaCO2 > 50 mm Hg or the use of home oxygen
• Documented deep venous thrombosis or pulmonary embolism within the preceding 3 months
• Inability/contra-indications to receiving local standard of care thromboprophylaxis
• Chronic immunosuppression (any chronic immunotherapy including daily oral steroid use >6months)
• Known HIV, Hep B/C positive, or active tuberculosis
• Multisystem shock (SOFA score change from baseline of >2 in >2 systems)
• Patient, surrogate, or physician not committed to full support including intubation (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

22 participants in 2 patient groups, including a placebo group

MSCs Arm

Experimental group

Description:

3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)

Treatment:

Biological: UC-MSCs

Placebo Arm

Placebo Comparator group

Description:

3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)

Treatment:

Biological: Placebo